Email updates

Keep up to date with the latest news and content from BMC Neurology and BioMed Central.

Open Access Research article

PET imaging of amyloid with Florbetapir F 18 and PET imaging of dopamine degeneration with 18F-AV-133 (florbenazine) in patients with Alzheimer’s disease and Lewy body disorders

Andrew Siderowf1, Michael J Pontecorvo1, Holly A Shill2, Mark A Mintun1, Anupa Arora1, Abhinay D Joshi1, Ming Lu1, Charles H Adler3, Douglas Galasko4, Carolyn Liebsack2, Daniel M Skovronsky1 and Marwan N Sabbagh2*

Author Affiliations

1 Avid Radiopharmaceuticals, Philadelphia, PA, USA

2 Banner Sun Health Research Institute, Sun City, AZ 10515W Santa Fe Dr, USA

3 Mayo Clinic Arizona, Scottsdale, AZ, USA

4 University of California, San Diego, CA, USA

For all author emails, please log on.

BMC Neurology 2014, 14:79  doi:10.1186/1471-2377-14-79

Published: 9 April 2014

Abstract

Background

Biomarkers based on the underlying pathology of Alzheimer’s disease (AD) and Dementia with Lewy Bodies (DLB) have the potential to improve diagnosis and understanding of the substrate for cognitive impairment in these disorders. The objective of this study was to compare the patterns of amyloid and dopamine PET imaging in patients with AD, DLB and Parkinson’s disease (PD) using the amyloid imaging agent florbetapir F 18 and 18F-AV-133 (florbenazine), a marker for vesicular monamine type 2 transporters (VMAT2).

Methods

Patients with DLB and AD, Parkinson’s disease (PD) and healthy controls (HC) were recruited for this study. On separate days, subjects received intravenous injections of florbetapir, and florbenazine. Amyloid burden and VMAT2 density were assessed quantitatively and by binary clinical interpretation. Imaging results for both tracers were compared across the four individual diagnostic groups and for combined groups based on underlying pathology (AD/DLB vs. PD/HC for amyloid burden and PD/DLB vs. AD/HC for VMAT binding) and correlated with measures of cognition and parkinsonism.

Results

11 DLB, 10 AD, 5 PD, and 5 controls participated in the study. Amyloid binding was significantly higher in the combined AD/DLB patient group (n = 21) compared to the PD/HC groups (n = 10, mean SUVr: 1.42 vs. 1.07; p = 0.0006). VMAT2 density was significantly lower in the PD/DLB group (n = 16) compared to the AD/ HC group (n = 15; 1.83 vs. 2.97; p < 0.0001). Within the DLB group, there was a significant correlation between cognitive performance and striatal florbenazine binding (r = 0.73; p = 0.011).

Conclusions

The results of this study show significant differences in both florbetapir and florbenazine imaging that are consistent with expected pathology. In addition, VMAT density correlated significantly with cognitive impairment in DLB patients (ClinicalTrials.gov identifier: NCT00857506, registered March 5, 2009).

Keywords:
PET imaging; Alzheimer’s disease; Parkinson’s disease; Biomarkers